mRNA新冠疫苗接种后2周内的反应原性:CDC v-safe监测系统的发现
基于美国CDC v-safe智能手机监测系统,分析2020年12月14日至2021年3月14日接种BNT162b2或mRNA-1273并完成至少一次调查的参与者,第1剂后7天内4,717,908人报告,第2剂后7天内2,906,377人报告,多数报告至少一种接种部位反应或全身反应,第2剂后及mRNA-1273接种者、<45岁者和女性反应原性更高,第2周新发或加重反应不常见。
要点
- 第1剂后68.5%报告至少一种接种部位反应,50.6%报告至少一种全身反应。
- 第2剂后72.9%报告至少一种接种部位反应,69.5%报告至少一种全身反应。
- 第2周新发或加重反应不常见,最常见为第1剂mRNA-1273接种者的局部反应(2.6%)。
研究设计与样本
- 对美国智能手机疫苗监测系统v-safe中接种BNT162b2或mRNA-1273后登记的人员进行监测,分析2020年12月14日至2021年3月14日接种且2021年3月28日前完成至少一次调查者的应答。
- 通过短信提示参与者完成网络调查,测量接种后第0至7天调查中报告的局部和全身反应比例,第14天调查以自由文本描述新发或加重症状。
主要发现
- 第1剂后7天内4,717,908人报告,第2剂后7天内2,906,377人报告。
- 第1剂后68.5%报告至少一种接种部位反应,50.6%报告至少一种全身反应;第2剂后72.9%报告至少一种接种部位反应,69.5%报告至少一种全身反应。
- 反应原性在第2剂后高于第1剂后,在mRNA-1273接种者、<45岁者和女性中更高。
- 第2周新发或加重局部和全身反应不常见,最常见为第1剂mRNA-1273接种者的局部反应(2.6%),第1剂mRNA-1273接种者女性中报告更频繁(3.6%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Post-authorization monitoring of mRNA-based COVID-19 vaccines is needed to better characterize their reactogenicity. We assessed reactions reported during the 2 weeks after receipt of BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines. METHODS: We monitored persons who enrolled in v-safe after vaccination health checkerSM, a U.S. smartphone-based vaccine monitoring system, after receiving BNT162b2 or mRNA-1273. V-safe participants received text message prompts to complete web-based surveys. We analyzed responses from persons who received BNT162b2 or mRNA-1273 from December 14, 2020 through March 14, 2021 and completed at least one survey by March 28, 2021. We measured the proportion of participants reporting local and systemic reactions solicited in surveys completed days 0 through 7 post-vaccination. For day 14 surveys, participants described new or worsening symptoms in a free-text response. We assessed the proportion of participants reporting new or worsening local and systemic reactions. RESULTS: One-third of participants were aged <45 years, two-thirds were female, and approximately half received BNT162b2 vaccine. A total of 4,717,908 participants reported during the 7 days after dose 1 and 2,906,377 reported during the 7 days after dose 2. Most reported at least one injection-site reaction (68.5% after dose 1; 72.9% after dose 2) or at least one systemic reaction (50.6% after dose 1; 69.5% after dose 2). Reactogenicity was greater after dose 2 and among mRNA-1273 recipients, persons aged <45 years, and females. New or worsening local and systemic reactions were uncommon during week 2 after either dose; the most frequent were local reactions for dose 1 mRNA-1273 recipients (2.6%). These reactions were reported more often among females after dose 1 mRNA-1273 (3.6%). CONCLUSIONS: During post-authorization monitoring among >4 million vaccinees, local and systemic reactions were commonly reported following mRNA-based vaccines. Reactions were most common during the first week following dose 2 and among persons aged <45 years, females, and mRNA-1273 recipients.
引用
- Chapin-Bardales J, Myers T, Gee J, et al. Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system. Vaccine. 2021. PMID: 34763946. doi:10.1016/j.vaccine.2021.10.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。